Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Tóm tắt
Từ khóa
Tài liệu tham khảo
Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5
Xu, 2020, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med, 10.1016/S2213-2600(20)30076-X
Miossec, 2012, Targeting IL-17 and TH17 cells in chronic inflammation, Nat Rev Drug Discov, 11, 763, 10.1038/nrd3794
Shimabukuro-Vornhagen, 2018, Cytokine release syndrome, J Immunother Cancer, 6, 56, 10.1186/s40425-018-0343-9
Norelli, 2018, Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells, Nat Med, 24, 739, 10.1038/s41591-018-0036-4
Teijaro, 2017, Cytokine storms in infectious diseases, Semin Immunopathol, 39, 501, 10.1007/s00281-017-0640-2
Chousterman, 2017, Cytokine storm and sepsis disease pathogenesis, Semin Immunopathol, 39, 517, 10.1007/s00281-017-0639-8
Leiva-Juarez, 2018, Lung epithelial cells: therapeutically inducible effectors of antimicrobial defense, Mucosal Immunol, 11, 21, 10.1038/mi.2017.71
Knudsen, 2018, The micromechanics of lung alveoli: structure and function of surfactant and tissue components, Histochem Cell Biol, 150, 661, 10.1007/s00418-018-1747-9
Brune, 2015, Pulmonary epithelial barrier function: some new players and mechanisms, Am J Physiol Lung Cell Mol Physiol, 308, L731, 10.1152/ajplung.00309.2014
Liu, 2020, Gross examination report of a COVID-19 death autopsy, Fa Yi Xue Za Zhi [Journal of Forensic Medicine], 36, 19
Scheller, 2006, Rose-John S. Interleukin-6 and its receptor: from bench to bedside, Med Microbiol Immunol, 195, 173, 10.1007/s00430-006-0019-9
Weissenbach, 1980, Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies, Proc Natl Acad Sci U S A, 77, 7152, 10.1073/pnas.77.12.7152
Hunter, 2015, IL-6 as a keystone cytokine in health and disease, Nat Immunol, 16, 448, 10.1038/ni.3153
Scheller, 2014, Interleukin-6: from basic biology to selective blockade of pro-inflammatory activities, Semin Immunol, 26, 2, 10.1016/j.smim.2013.11.002
Jones, 2018, Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer, Nat Rev Immunol, 18, 773, 10.1038/s41577-018-0066-7
Yamasaki, 1988, Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor, Science, 241, 825, 10.1126/science.3136546
Baran, 2018, The balance of interleukin (IL)-6, IL-6•soluble IL-6 receptor (sIL-6R), and IL-6•sIL-6R•sgp130 complexes allows simultaneous classic and trans-signaling, J Biol Chem, 293, 6762, 10.1074/jbc.RA117.001163
Briso, 2008, Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells, J Immunol, 180, 7102, 10.4049/jimmunol.180.11.7102
Campbell, 2014, Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain, J Neurosci, 34, 2503, 10.1523/JNEUROSCI.2830-13.2014
Jones, 2005, Directing transition from innate to acquired immunity: defining a role for IL-6, J Immunol, 175, 3463, 10.4049/jimmunol.175.6.3463
Johnson, 2018, Targeting the IL-6/JAK/STAT3 signalling axis in cancer, Nat Rev Clin Oncol, 15, 234, 10.1038/nrclinonc.2018.8
Villarino, 2017, Mechanisms and consequences of Jak-STAT signaling in the immune system, Nat Immunol, 18, 374, 10.1038/ni.3691
Zegeye, 2018, Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells, Cell Commun Signal, 16, 55, 10.1186/s12964-018-0268-4
Su, 2017, Interleukin-6 signaling pathway and its role in kidney disease: an update, Front Immunol, 8, 405, 10.3389/fimmu.2017.00405
Heinrich, 2003, Principles of interleukin (IL)-6-type cytokine signalling and its regulation, Biochem J, 374, 1, 10.1042/bj20030407
Taniguchi, 2015, A gp130-Src-YAP module links inflammation to epithelial regeneration, Nature, 519, 57, 10.1038/nature14228
Yamada, 2012, JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells, Mol Cancer Ther, 11, 1112, 10.1158/1535-7163.MCT-11-0850
Thiem, 2013, mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice, J Clin Invest, 123, 767
Yasukawa, 1987, Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene, EMBO J, 6, 2939, 10.1002/j.1460-2075.1987.tb02598.x
Jones, 2018, IL-6: a cytokine at the crossroads of autoimmunity, Curr Opin Immunol, 55, 9, 10.1016/j.coi.2018.09.002
Bettelli, 2006, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature, 441, 235, 10.1038/nature04753
Schmidt-Arras, 2016, IL-6 pathway in the liver: from physiopathology to therapy, J Hepatol, 64, 1403, 10.1016/j.jhep.2016.02.004
Fraunberger, 2006, Prognostic value of interleukin 6, procalcitonin, and C-reactive protein levels in intensive care unit patients during first increase of fever, Shock, 26, 10, 10.1097/01.shk.0000215319.06866.bd
Campard, 2006, Multilevel regulation of IL-6R by IL-6–sIL-6R fusion protein according to the primitiveness of peripheral blood-derived CD133+ cells, Stem Cells, 24, 1302, 10.1634/stemcells.2005-0173
Kraakman, 2015, Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance, Cell Metab, 21, 403, 10.1016/j.cmet.2015.02.006
Qu, 2014, IL-6 in diabetes and cardiovascular complications, Br J Pharmacol, 171, 3595, 10.1111/bph.12713
Navarro, 2014, Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums, Semin Arthritis Rheum, 43, 458, 10.1016/j.semarthrit.2013.08.001
Yokota, 2005, Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 52, 818, 10.1002/art.20944
Nishimoto, 2005, Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease, Blood, 106, 2627, 10.1182/blood-2004-12-4602
Ito, 2004, A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease, Gastroenterology, 126, 989, 10.1053/j.gastro.2004.01.012
Grupp, 2013, Chimeric antigen receptor-modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134
Winkler, 1999, Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8), Blood, 94, 2217, 10.1182/blood.V94.7.2217.419k02_2217_2224
2019
Xu X.L., Han M.F., Li T.T., Sun W., Wang D.S., Fu B.Q., et al. Effective treatment of severe COVID-19 patients with tocilizumab. http://chinaxiv.org/abs/202003.00026[accessed 11 March 2020].
2020, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China [in Chinese], Zhonghua Liu Xing Bing Xue Za Zhi, 41, 145
Giles, 2020, Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial, Arthritis Rheumatol, 72, 31, 10.1002/art.41095
Kim, 2017, Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study, Arthritis Rheumatol, 69, 1154, 10.1002/art.40084
Xie, 2019, Tocilizumab and the risk of cardiovascular disease: direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients, Arthritis Care Res, 71, 1004, 10.1002/acr.23737
Le, 2018, FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome, Oncologist, 23, 943, 10.1634/theoncologist.2018-0028
Teachey, 2013, Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy, Blood, 121, 5154, 10.1182/blood-2013-02-485623
Castilletti, 2005, Coordinate induction of IFN-α and -γ by SARS-CoV also in the absence of virus replication, Virology, 341, 163, 10.1016/j.virol.2005.07.015
Shi, 2006, The expression of membrane protein augments the specific responses induced by SARS-CoV nucleocapsid DNA immunization, Mol Immunol, 43, 1791, 10.1016/j.molimm.2005.11.005
Tseng, 2005, Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection, J Immunol, 174, 7977, 10.4049/jimmunol.174.12.7977
Zheng, 2016, Bioinformatics analysis on molecular mechanism of ribavirin and interferon-α in treating MERS-CoV [in Chinese], Zhonghua Liu Xing Bing Xue Za Zhi, 37, 291
The State Council of the People's Republic of China. Diagnosis and treatment protocol for novel coronavirus pneumonia (seventh edition). http://www.gov.cn/zhengce/zhengceku/2020-03/04/5486705/files/ae61004f930d47598711a0d4cbf874a9.pdf[accessed 12 March 2020].